<DOC>
	<DOCNO>NCT00978380</DOCNO>
	<brief_summary>This trial conduct Asia , Europe North America . The aim trial investigate safety monthly replacement therapy recombinant factor XIII patient congenital FXIII deficiency . The trial continue product commercially available , interim assessment take place subject complete 52 week trial .</brief_summary>
	<brief_title>Safety Monthly Recombinant Factor XIII Replacement Therapy Subjects With Congenital Factor XIII Deficiency : An Extension Trial F13CD-1725</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor XIII Deficiency</mesh_term>
	<criteria>For subject participate F13CD1725 : Previous participation ( mean inclusive Visit 16 , ( End Trial ) ) F13CD1725 For subject : Diagnosis congenital FXIII Asubunit deficiency ( confirm genotyping screen visit document result previously perform genotyping ) Body weight least 20 kg Known neutralizing antibody ( inhibitor ) towards FXIII Any known congenital acquire coagulation disorder congenital FXIII deficiency Platelet count ( thrombocyte ) less 50 Ã— 109/L . For subject participate F13CD1725 platelet count visit 15 F13CD1725 must use evaluation . Females childbearing potential pregnant , breastfeed use adequate contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>